MDLZ three-lens brief
Evidence-based stock research on MDLZ. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Analyst mean target $67.27 — 16% above current (22 analysts). · Trading >3% below the 50-day MA — short-term weakness.
- Trading >3% below the 50-day MA — short-term weakness.
- Analyst mean target $67.27 — 16% above current (22 analysts).
- Earnings scheduled 2026-07-28.
MDLZ closed at $58.06 (-0.40%) as of 2026-07-10. Market cap: $74.54B. P/E (trailing) 28.7. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $67.27 — 16% above current (22 analysts).. Concerns: trading >3% below the 50-day MA — short-term weakness.. Last quarter: Revenue $10.08B, net income $560.00M, free cash flow $2.85B. Watching for: 2026-07-28 earnings release (17 days out).
Why three lenses on MDLZ, not one.
A single reasoning model has blind spots it doesn’t know about. We examine MDLZacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/MDLZ" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath MDLZ brief"></iframe>